Silvia Coma

Senior Director, Translational & Preclinical Research Verastem Oncology

Seminars

Tuesday 16th September 2025
The FAK Inhibitor Defactinib Augments the Anti-Tumor Efficacy of the RAF/MEK Inhibitor Avutometinib for Patients with KRAS Mutant Cancers
1:45 pm
  • Scientific rationale leading to approval for patients with KRAS mutant low-grade serous ovarian cancer (LGSOC)
  • Preclinical rationale and clinical update for patients with KRAS mutant PDAC and NSCLC
  • Implications for FAK inhibitor combinations with the new generation of KRAS inhibitors
Silvia Coma